| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEWS |
1 Oral Medicine, Division of Maxillofacial Diagnostic, Medical & Surgical Sciences, Eastman Dental Institute for Oral Health Care Sciences, UCL, University of London, 256, Gray’s Inn Road, London WC1X 8LD, UK;
2 Community Dental Department, Coventry NHS Primary Care Trust, Abbey View, 271 London Road, Coventry, West Midlands CV3 4AR, UK;
3 Department of Nephrology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, West Midlands CV2 2DX, UK; and
4 Health Services Research, Eastman Dental Institute for Oral Health Care Sciences, UCL, University of London, 256, Gray’s Inn Road, London WC1X 8LD, UK;
* corresponding author, S.Porter{at}eastman.ucl.ac.uk
 |
ABSTRACT |
|---|
 TOP ABSTRACT (I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
KEY WORDS: chronic • dental • oral • renal
|
(I) INTRODUCTION |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
|
(II) CHRONIC RENAL FAILURE |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
|
(III) EPIDEMIOLOGY |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
The death rate is 178, 189, 217, and 209 per 1000 patient years (pyr) in the USA, Australia, New Zealand, and the UK, respectively (Table 1
). These figures suggest that the USA has a lower death rate than the UK, but the USA data do not include deaths in the first 90 days following the onset of chronic renal failure. However, the UK death rate at 1 year and 90 days (188/1000 pyr) is comparable with that in the USA. There are only slight differences in the death rates between genders. Ethnicity also affects death rate: In the USA, it is lowest in Asians (130/1000 pyr) and highest in Caucasians (193/1000 pyr).
|
The most common cause of death is cardiac failure, followed by infection and malignancy (Ansell and Feest, 2002; McDonald and Russ, 2002; US Renal Data System, 2002). Diabetes mellitus and hypertension greatly increase this risk (Santiago and Chanzan, 1989).
|
(IV) CLINICAL FEATURES |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
and 3 outline the signs, symptoms, and clinical features of CRF (Stein and Wild, 2002).
|
|
|
(V) TREATMENT OF CHRONIC RENAL FAILURE |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
Dietary and fluid restrictions may be required to accommodate the reduced excretory capacity of the kidneys. Acidosis and increased levels of potassium can be treated by reducing dietary intake of potassium-rich foods, such as bananas, and sodium restriction can aid the control of hypertension. It is sometimes necessary to reduce protein consumption to minimize nitrogenous waste products. Despite this treatment, most patients progress to end-stage renal failure (ESRF), requiring dialysis or transplantation.
(a) Dialysis
There are two types of dialysis: hemodialysis and peritoneal dialysis (PD). In each case, the patient’s blood is separated from the dialysis fluid (dialysate) by a membrane which allows water and toxins, but not blood cells, to pass out of the blood. In PD, the peritoneal membrane acts as the filter, whereas, in hemodialysis, the membrane is within the dialysis machine. Individuals commonly commence with PD and may progress to hemodialysis if renal function deteriorates further.
Most affected patients receive hemodialysis for up to 4 hrs, 2 or 3 times each week (Ansell and Feest, 2002). Arteriovenous fistulae in the arm are required for regular vascular access via wide-bore needles. The fistula is usually fashioned from a native vein; however, it is sometimes necessary to use animal or synthetic grafts if the local anatomy is unsuitable (Werner and Saad, 1999). Hemodialysis increases the risk of viral transmission (such as HIV and hepatitis B and C; Pol, 1995) and is costly.
In comparison of the cost-effectiveness of hemodialysis and PD, one finds that the latter has less initial cost, but the long-term cost of the two techniques is similar. Although the two techniques are equally effective and appropriate for most patients, it is common, at least in the UK, to begin with PD, since the veins will be available should the technique fail and hemodialysis become necessary (Stein and Wild, 2002).
For PD to take place, a catheter is placed into the peritoneum through which the dialysis fluid is exchanged. Continuous ambulatory peritoneal dialysis (CAPD) requires 4 exchanges of approximately 2 liters throughout the day. An alternative method is automated peritoneal dialysis (APD), in which the dialysis fluid exchanges are carried out automatically by machine, during the hours of sleep (for 8–10 hrs).
(b) Renal Transplantation
Renal allografts may be cadaveric or from living donors, either related or non-related (although those from living relatives give rise to the best prognosis). Cadaveric organs are allocated on the basis of HLA tissue-typing, ABO compatibility, and the age and size of the donor and recipient.
In the UK, during 2001, 1743 (29.6 per million population) kidney transplant operations were perfomed (http://www.uktransplant.org.uk/statistics/transplant_activity/, http://www.statistics.gov.uk/census2001/pop2001/united_kingdom.asp). These consisted of 1385 cadaveric and 358 living donor renal transplants. The majority (263) of the living donors were relatives. The one-year success rate is presently 86% for cadaveric- and 95% for living-donor-transplanted kidneys (www.uktransplant.org.uk/). The principal cause of allograft failure is rejection, although adverse drug side-effects may also be a contributing factor.
Immunosuppressant therapy is required to minimize the risk of allograft rejection. Commonly used agents are prednisolone, azathioprine, cyclosporin, and, more recently, tacrolimus. Cyclosporin has been associated with potentially serious side-effects, including nephrotoxicity (Grinyo and Cruzado, 2004), hepatotoxicity, neurotoxicity, hypertrichosis, and diabetes mellitus (Ota and Bradley, 1983; Svirsky and Saravia, 1989; Pirsch et al., 1997; Al-Zayer et al., 2001). Tacrolimus has adverse side-effects similar to those of cyclosporin, such as nephrotoxicity and neurotoxicity (Mihatsch et al., 1998); however, diabetes is a more frequent complication (Zuckermann et al., 2003) and occurs in up to 37% of patients receiving tacrolimus (McDonald and Russ, 2002). Hypertension and cytomegalovirus infection are less common with tacrolimus than with cyclosporin therapy. In addition to immunosuppressants, recipients of renal allografts require an array of medications, some of which can give rise to oral side-effects (see below).
|
(VI) ORAL MANIFESTATIONS OF CHRONIC RENAL FAILURE AND RELATED THERAPIES |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
(i) Cyclosporin-induced Gingival Enlargement
The prevalence of gingival enlargement in individuals taking cyclosporin is unclear, and reportedly has a wide range—from 6 to 85% (Seymour et al., 1987; Slavin and Taylor, 1987; Pan et al., 1992; Pernu et al., 1992; King et al., 1993; Thomason et al., 1993; Allman et al., 1994; Somacarrera et al., 1994). It can be evident within 3 mos of the initiation of cyclosporin therapy (Savage et al., 1987; Thomason et al., 1996). Children and adolescents may be more prone to this drug-induced gingival enlargement than adults. If oral hygiene is poor, older individuals are also prone to gingival enlargement (Seymour and Smith, 1991).
Improvement in oral hygiene and professional cleaning results in a reduction in cyclosporin-associated gingival enlargement (Thomason et al., 1993, 1996; Somacarrera et al., 1994; Fu et al., 1997). However, this may be due to reduction in plaque-related inflammation rather than any drug-associated gingival enlargement (Seymour and Smith, 1991). There are conflicting reports on the association between gingival enlargement and cyclosporin dose (Porter and Scully, 1994), but the extent of the gingival enlargement does not seem to be related to the function of the allograft (Thomas et al., 2001).
Regular clinical monitoring of cyclosporin-related gingival enlargement is essential, since squamous cell carcinoma (Varga and Tyldesley, 1991) and Kaposi’s sarcoma have been reported within such gingival lesions (Qunibi et al., 1988; Farge, 1993).
(ii) Calcium Channel-blocker-induced Gingival Enlargement
Calcium channel blockers are prescribed to renal allograft recipients to reduce hypertension and cyclosporin-induced nephrotoxicity (Morales et al., 1994). There are many reports of nifedipine, amlodipine (Seymour et al., 1994; Ellis et al., 1999), diltiazem (Colvard et al., 1986; Giustiniani et al., 1987; Bowman et al., 1988; King et al., 1993), verapamil (Cucchi et al., 1985; Pernu et al., 1989), oxidipine, felodipine, and nitrendipine (Hassell and Hefti, 1991; Rees and Levine, 1995) causing this gingival enlargement. The reported prevalence of nifedipine-induced gingival enlargement is variable and occurs in 10–83% of treated patients (Seymour et al., 1987; Barclay et al., 1992; Ellis et al., 1999). There are no data on the frequency of gingival enlargement with the other calcium channel blockers.
The presence of dental plaque may predispose to nifedipine-induced gingival enlargement (Nishikawa et al., 1991), but is not essential to its development (Morisaki et al., 1993). The dose or duration of treatment is not related to the prevalence of gingival enlargement (Barclay et al., 1992; Ellis et al., 1993). Some studies have reported a reduction in gingival enlargement following a change to an alternative calcium channel blocker (Lederman et al., 1984; Cebeci et al., 1996), but these drugs can still cause some gingival enlargement (Westbrook et al., 1997).
(iii) Combined Cyclosporin and Calcium Channel-blocker Therapy
There may be an increased incidence (Thomason et al., 1995, 1996; Margiotta et al., 1996; McKaig et al., 2002) and severity (King et al., 1993, 1994; Thomason et al., 1993, 1995, 1996; O’Valle et al., 1995; Margiotta et al., 1996; McKaig et al., 2002) of gingival enlargement when cyclosporin and nifedipine are prescribed together. In contrast, the combination of verapamil with cyclosporin does not seem to increase the frequency or severity of drug-induced gingival enlargement significantly (Cebeci et al., 1996).
(iv) Tacrolimus
Tacrolimus has been reported both to cause (Adams and Famili, 1991; Spencer et al., 1997) and to lessen (Asante-Korang et al., 1996; Cox and Freese, 1996) gingival enlargement, although, in a recent study of children with renal allografts, while 41% of those receiving cyclosporin had gingival enlargement, the majority of those receiving tacrolimus did not have this problem (Sheehy et al., 2000). Cyclosporin-associated gingival enlargement may reduce or resolve when cyclosporin is replaced by tacrolimus (Dodd, 1997; Bader et al., 1998; Busque et al., 1998; Hernandez et al., 1998, 2000; James et al., 2000; Kennedy and Linden, 2000).
(v) Other Gingival Changes
The gingivae in individuals with CRF can be pale due to anemia (Lohr and Schwab, 1991; London and Drueke, 1997), with possible loss of the demarcation of the mucogingival junction (Buckley et al., 1986), and when there is platelet dysfunction, the gingivae may bleed easily (Opatry, 1997).
(b) Oral Hygiene and Periodontal Disease
The oral hygiene of individuals receiving hemodialysis can be poor. For example, only 15% of 45 individuals receiving hemodialysis from 4 centers in Virginia, USA, had a good standard of oral hygiene (Naugle et al., 1998). Deposits of calculus may be increased (Epstein et al., 1980; Jaffe et al., 1986; Gavalda et al., 1999).
There is no good evidence of an increased risk of periodontitis (Brown et al., 1989; Thorstensson et al., 1996; Naugle et al., 1998), although premature tooth loss has been reported (Locsey et al., 1986). Localized suppurative osteomyelitis, secondary to periodontitis, was observed in one individual receiving hemodialysis (Tomaselli et al., 1993).
(c) Xerostomia
Symptoms of xerostomia can arise in many individuals receiving hemodialysis (Eigner et al., 1986; Gavalda et al., 1999; Kho et al., 1999; Kao et al., 2000; Klassen and Krasko, 2002). Possible causes include restricted fluid intake, side-effects of drug therapy, and/or mouth-breathing. Long-term xerostomia may predispose to caries and gingival inflammation and can give rise to difficulties with speech, denture retention, mastication, dysphagia, sore mouth, and loss of taste (Porter et al., 2004).
It also predisposes to caries and infections such as candidosis and acute suppurative sialadenitis (Porter et al., 2004).
(d) Oral Malodor/Bad Taste
Uremic patients may have an ammonia-like oral odor (Eigner et al., 1986; Kho et al., 1999), which also occurs in about one-third of individuals receiving hemodialysis (Kho et al., 1999). Chronic renal failure can give rise to altered taste sensation, and some patients complain of an unpleasant and/or metallic taste (Levy, 1988), or a sensation of an enlarged tongue (Levy, 1988; Ray, 1989; Kho et al., 1999).
(e) Mucosal Lesions
A wide range of oral mucosal lesions, particularly white patches and/or ulceration, has been described in individuals receiving dialysis and allografts (Table 4). In particular, lichen-planus-like disease (sometimes termed lichenoid disease) can arise, sometimes, but not always, as a consequence of the associated drug therapy (e.g., diuretics, beta-blockers) (Chau et al., 1984; Hogan et al., 1985; Markitziu et al., 1986; Torrelo et al., 1990). Similarly, oral hairy leukoplakia can occur secondary to drug-related immunosuppression (Greenspan and Greenspan, 1989; King et al., 1993, 1994), although clinically and histopathologically similar lesions lacking Epstein-Barr virus (EBV) have been observed with uremia (McCreary et al., 1997). Of note, this latter lesion may resolve with correction of the uremia.
|
In some instances, the mucosal surface may become erythematous or ulcerate (King et al., 1994; Kho et al., 1999; Klassen and Krasko, 2002). Oral mucosal macules and nodules have also been described in 14% of individuals receiving hemodialysis (Klassen and Krasko, 2002). Other lesions that can occur intra-orally in allograft recipients are listed in Table 4
(King et al., 1994).
(f) Oral Malignancy
The risk of oral squamous cell carcinoma in patients receiving hemodialysis is generally similar to that of otherwise healthy individuals in the general population (Lee and Gisser, 1978; Bradford et al., 1990), although there have been reports suggesting that therapy following renal transplantation predisposes to epithelial dysplasia and carcinoma of the lip (Regev et al., 1992; Thomas et al., 1993). Perhaps unsurprisingly, Kaposi’s sarcoma (KS) can occur in the mouths of immunosuppressed renal transplant recipients (Farge, 1993). There have been reports of squamous cell carcinoma (Varga and Tyldesley, 1991) and KS (Qunibi et al., 1988) arising within areas of cyclosporin-induced gingival enlargement. Any increased risk of oral malignancy in CRF probably reflects the effects of iatrogenic immunosuppression, which increases liability to virally associated tumors, such as Kaposi’s sarcoma or non-Hodgkin’s lymphoma. The inconsistent association between oral epithelial dysplasia and oral squamous cell carcinoma is in accord with the low risk of such disease in individuals with other, more significant, immunosuppressed states—for example, HIV disease.
(g) Oral Infections
(i) Candidosis
Angular cheilitis has been described in up to 4% of hemodialysis and renal allograft recipients (King et al., 1994; Klassen and Krasko, 2002). Other oral candidal lesions—such as pseudomembranous (1.9%), erythematous (3.8%), and chronic atrophic candidosis (3.8%)—have been reported in allograft recipients (King et al., 1994). These figures may underestimate the increased susceptibility of immunosuppressed allograft recipients to fungal infection, since systemic anti-fungal agents are commonly prescribed prophylactically (Quirk et al., 1995).
(ii) Viral Infection
Prior to the availability of appropriate anti-viral drugs (e.g., acyclovir, gancyclovir, and valacyclovir), about 50% of renal allograft recipients, who were seropositive for herpes simplex, experienced recurrent, severe, and prolonged HSV infections (Korsager et al., 1975; Armstrong et al., 1976; Naraqi et al., 1977). However, in recent years, the use of effective anti-herpetic regimes has significantly reduced the frequency of such infection (Kletzmayr et al., 2000; Ljungman, 2001; McGavin and Goa, 2001; Squifflet and Legendre, 2002). Long-standing post-allograft immunosuppression may predispose subjects to human herpesvirus 8 (HHV-8) and associated Kaposi’s sarcoma (Leao et al., 2000).
(h) Dental Anomalies
Delayed eruption of permanent teeth has been reported in children with CRF (Woodhead et al., 1982; Koppang et al., 1984; Sampson and Meister, 1984; Wolff et al., 1985; Carl, 1987; Levy, 1988; Jaffe et al., 1990). Enamel hypoplasia of the primary and permanent teeth (Wolff et al., 1985; Kho et al., 1999; Koch et al., 1999; Al Nowaiser et al., 2003), with or without brown discoloration (Bottomley et al., 1972; Woodhead et al., 1982; Wolff et al., 1985; Eigner et al., 1986; Carl, 1987; Levy, 1988), can also occur.
Narrowing or calcification of the pulp chamber of teeth of adults with chronic renal disease can occur (Kelly et al., 1980; Spolnik et al., 1981; Wysocki et al., 1983; Nasstrom et al., 1985, 1993; Galili et al., 1991; Nasstrom, 1996; Ganibegovic, 2000). The exact cause of this dental change is not known. Renal allograft recipients have significantly more narrowing of the pulp chamber than those receiving hemodialysis (Nasstrom et al., 1985). There is no consistent association between corticosteroid therapy and narrowing of the pulp chamber (Galili et al., 1991).
Increased (Locsey et al., 1986) and decreased rates of dental caries (Woodhead et al., 1982; Sampson and Meister, 1984; Wolff et al., 1985; Jaffe et al., 1986; Levy, 1988; Klassen and Krasko, 2002; Al Nowaiser et al., 2003) have been observed in groups of patients with CRF. However, there is no evidence of a significantly increased risk of caries in patients with CRF. Although patients may have xerostomia, there would seem to be no increased risk of cervical caries, as might be expected (Porter et al., 2004).
Non-carious tooth tissue loss is more prevalent in individuals with CRF than in the general population (Levy, 1988). This may be due to nausea (Levy, 1988), esophageal regurgitation, or induced vomiting in bulimia nervosa (if a patient finds the restricted diet unpleasant) (Levy, 1988; Klassen and Krasko, 2002).
(i) Bone Lesions
A wide range of bony anomalies can arise in chronic renal disease. These reflect a variety of defects of calcium metabolism, including: loss of hydroxylation of 1-hydroxycholecalciferol to active vitamin D (1,25-dihydroxycholecalciferol); decreased hydrogen ion excretion (and resultant acidosis); hyperphosphatemia; hypocalcemia and resultant secondary hyperparathyroidism; and finally, interference in phosphate biochemistry by dialysis (Nadimi et al., 1993).
Secondary hyperparathyroidism affects up to 92% of patients receiving hemodialysis (Massry and Ritz, 1978). Hyperparathyroidism may present as a maxillary brown tumor (Okada et al., 2000), enlargement of the skeletal bases (Nadimi et al., 1993; Phelps et al., 1994; Michiwaki et al., 1996; Damm et al., 1997; Vigneswaran, 2001), or tooth mobility (Carmichael et al., 1995).
Orofacial features of renal osteodystrophy due to hyperparathyroidism are listed in Tables 5 and 6 (Sampson and Meister, 1984; Locsey et al., 1986; Carl, 1987; Levy, 1988; Molpus et al., 1991; Nadimi et al., 1993; Michiwaki et al., 1996; Damm et al., 1997; Ganibegovic, 2000; Okada et al., 2000; Klassen and Krasko, 2002).
|
|
|
(VII) DENTAL MANAGEMENT OF PATIENTS WITH CHRONIC RENAL FAILURE |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
It has been recommended that patients requiring a renal transplant have a detailed oral assessment and treatment prior to surgery (Kirkpatrick and Morton, 1971; Sowell, 1982; Eigner et al., 1986; Naylor and Fredericks, 1996; Ferguson and Whyman, 1998), perhaps highlighting a need for appropriately trained oral health professionals to collaborate with renal physicians. The dental examination should be timed appropriately to allow any necessary dental treatment to be carried out in a planned manner (Klassen and Krasko, 2002). Most transplant centers worldwide have a dental check in their pre-transplant protocol (Yamalik et al., 1993). However, Klassen and Krasko (2002) found that pre-transplant oral care was not meticulous. There is no evidence that poor oral hygiene or consequent dental disease significantly affects the morbidity or mortality associated with CRD. Nevertheless, there have been very occasional reports of the severe local and systemic spread of odontogenic infection in renal transplant recipients (Reyna et al., 1982; Wilson et al., 1982).
There may be a bleeding tendency in hemodialysis recipients, due to anti-coagulants or platelet dysfunction, but its effects can be minimized if dental treatment is carried out on the day following dialysis (Stewart, 1967; Dobkin et al., 1978; Precious et al., 1981; Sowell, 1982; Mannucci et al., 1983; Buckley et al., 1986; Eschbach and Adamson, 1989; Jameson and Wiegmann, 1990; De Rossi and Glick, 1996; Naylor and Fredericks, 1996). This is a practical solution, since the patients will still be in the hospital.
To minimize the risk of adrenal crisis in individuals who have taken large doses of corticosteroid (10 mg prednisolone daily or equivalent during the preceding 3 mos) and undergoing major surgical procedures (such as extraction of more than one tooth), appropriate corticosteroid cover should be administered (Seymour et al., 1994). In the past, large doses were used (up to 200 mg hydrocortisone), but more recent guidelines have recommended lower physiological doses (25 mg intravenous hydrocortisone pre-operatively) (Nicholson et al., 1998).
Impaired renal function can result in high blood levels of drugs or their metabolites (Perneger et al., 1994); thus, it may be necessary to reduce the dosage of many drugs or use alternative agents (Bennett et al., 1983). Potential medication complications are listed in Table 7 (British National Formulary, 2002).
|
The ideal management of drug-induced gingival enlargement is to substitute another drug (Khocht and Schneider, 1997), but this may not always be possible. Meticulous oral hygiene (Daley et al., 1986; Hassell and Hefti, 1991; Nishikawa et al., 1991; Seymour and Smith, 1991; Hancock and Swan, 1992; Somacarrera et al., 1996, 1997; Hall, 1997; Westbrook et al., 1997; Bader et al., 1998; Oettinger-Barak et al., 2000) can lessen any plaque-related gingival disease, but there may still be some drug-associated gingival enlargement. Single case reports have advocated the use of antimicrobial agents (Nash and Zaltzman, 1998; Wirnsberger et al., 1998) such as metronidazole (Wong et al., 1994) to lessen the gingival enlargement, but metronidazole may also increase the cyclosporin concentration and the potential for nephrotoxicity (Seymour et al., 1997). Scalpel or laser excision of the gingival enlargement is necessary if the excess gingival tissue is unsightly and/or interferes with mastication, speech, or oral care (Khocht and Schneider, 1997). Recurrence is common, especially when the oral hygiene is inadequate (Seymour et al., 1994; Hall, 1997), highlighting the need for long-term effective plaque control and consideration of additional anti-plaque measures such as topical chlorhexidine gluconate or triclosan preparations.
|
CONCLUSION |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
Received March 16, 2004; Accepted August 1, 2004
|
REFERENCES |
|---|
|
TOPABSTRACT(I) INTRODUCTION(II) CHRONIC RENAL FAILURE(III) EPIDEMIOLOGY(IV) CLINICAL FEATURES(V) TREATMENT OF CHRONIC...(VI) ORAL MANIFESTATIONS OF...(VII) DENTAL MANAGEMENT OF...CONCLUSIONREFERENCES |
|---|
Al Nowaiser A, Roberts GJ, Trompeter RS, Wilson M, Lucas VS (2003). Oral health in children with chronic renal failure. Pediatr Nephrol 18:39–45.[ISI][Medline]
Al-Zayer M, da Fonseca M, Ship JA (2001). Pyogenic granuloma in a renal transplant patient: case report. Spec Care Dentist 21:187–190.[Medline]
Allman SD, McWhorter AG, Seale NS (1994). Evaluation of ciclosporin-induced gingival overgrowth in pediatric transplant patients. Pediatr Dent 16:35–40.
Ansell D, Feest T, editors (2002). UK Renal Registry Report 2002. Bristol, UK: UK Renal Registry.
Armstrong JA, Evans AS, Rao N, Ho M (1976). Viral infections in renal transplant recipients. Infect Immun 14:970–975.
Asante-Korang A, Boyle GJ, Webber SA, Miller SA, Fricker FJ (1996). Experience of FK506 immune suppression in paediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 15:415–422.[ISI][Medline]
Bader G, Lejeune S, Messner M (1998). Reduction of ciclosporin-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient. J Periodontol 69:729–732.[ISI][Medline]
Barclay S, Thomason JM, Idle JR, Seymour RA (1992). The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 19:311–314.[ISI][Medline]
Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, et al. (1983). Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 3:155–193.[ISI][Medline]
Bottomley WK, Cioffi RF, Martin AJ (1972). Dental management of the patient treated by renal transplantation: preoperative and postoperative considerations. J Am Dent Assoc 85:1330–1335.[ISI][Medline]
Bowman JM, Levey BA, Grubb RV (1988). Gingival overgrowth induced by diltiazem. Oral Surg Oral Med Oral Pathol 65:183–185.[ISI][Medline]
Bradford CR, Hoffman HT, Wolf GT, Carey TE, Baker SR, McClatchey KD (1990). Squamous carcinoma of the head and neck in organ transplant recipients: possible role of oncogenic viruses. Laryngoscope 100:190–194.[ISI][Medline]
British National Formulary 44 (2002). London: British Medical Association.
Brown LJ, Oliver RC, Löe H (1989). Periodontal diseases in the US in 1981: prevalence, severity, extent and role in tooth mortality. J Periodontol 60:353–370.
Buckley DJ, Barrett AP, Koutts J, Stewart JH (1986). Control of bleeding in severely uremic patients undergoing oral surgery. Oral Surg Oral Med Oral Pathol 61:546–549.[ISI][Medline]
Busque S, Derners P, St Louis G, Boily JG, Tousignant J, Lemieux F, et al. (1998). Conversion from Neoral (ciclosporin) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transpl Proc 30:1247–1248.[ISI][Medline]
Carl W (1987). Chronic renal disease and hyperparathyroidism: dental manifestations and management. Compend Contin Educ Dent 8:697–704.
Carmichael DT, Williams CA, Aller MS (1995). Renal dysplasia with secondary hyperparathyroidism and loose teeth in a young dog. J Vet Dent 12:143–146.[Medline]
Cebeci I, Kantarci A, Firatli E, Carin M, Tuncer O (1996). The effect of verapamil on the prevalence and severity of ciclosporin-induced gingival overgrowth in renal allograft recipients. J Periodontol 67:1201–1205.[ISI][Medline]
Chau NY, Reade PC, Rich AM, Hay KD (1984). Allopurinol-amplified lichenoid reactions of the oral mucosa. Oral Surg Oral Med Oral Pathol 38:397–400.
Colvard MD, Bishop J, Weissman D, Bargiulo AV (1986). Cardiazem-induced gingival hyperplasia. Periodontal Case Rep 8:67–68.[Medline]
Cox KL, Freese DK (1996). Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in paediatric liver transplantation. Clin Invest Med 19:389–392.[ISI][Medline]
Cucchi G, Giustiniani S, Robustelli F (1985). Gingival hyperplasia caused by verapamil. Ital J Cardiol 15:556–557.
Daley TD, Wysocki GP, May C (1986). Clinical and pharmacological correlations in ciclosporin-induced gingival hyperplasia. Oral Surg 62:417–421.
Damm DD, Neville BW, McKenna S, Jones AC, Freedman PD, Anderson WR, et al. (1997). Macrognathia of renal osteodystrophy in dialysis patients. Oral Surg Oral Med Oral Pathol 83:489–495.
De Rossi S, Glick M (1996). Dental considerations for the patient with renal disease receiving haemodialysis. J Am Dent Assoc 127:211–219.
Dobkin JF, Miller MH, Steigbigel NH (1978). Septicemia in patients on chronic hemodialysis. Ann Intern Med 88:28–33.
Dodd DA (1997). Rapid resolution of gingival hyperplasia after switching from cyclosporine A to tacrolimus (abstract). J Heart Lung Transplant 16:579.[ISI][Medline]
Eigner TL, Justak TJ, Bennett WM (1986). Achieving oral health in patients with renal failure and renal transplants. J Am Dent Assoc 113:112–114.
Ellis JS, Seymour RA, Monkman SC, Idle JR (1993). Disposition of nifedipine in plasma and gingival crevicular fluid in relation to drug-induced gingival overgrowth. J Periodontal Res 28:373–378.[ISI][Medline]
Ellis JS, Seymour RA, Steele J, Robertson P, Butler TJ, Thomason JM (1999). Prevalence of gingival overgrowth induced by calcium channel blockers: a community based study. J Periodontol 70:63–67.[ISI][Medline]
Epstein SR, Mandell L, Scopp IW (1980). Salivary composition and calculus formation in patients undergoing hemodialysis. J Periodontol 51:336–338.[ISI][Medline]
Eschbach JW, Adamson JW (1989). Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis 14(Suppl 1):2–8.[ISI][Medline]
Farge D (1993). Kaposi’s sarcoma in organ transplant recipients. Eur J Med 2:339–343.[Medline]
Ferguson CA, Whyman RA (1998). Dental management of people with renal disease and renal transplants. New Zealand Dent J 94:125–130.
Fu E, Nieh S, Wikesjo UME (1997). The effect of plaque retention on ciclosporin-induced gingival overgrowth in rats. J Periodontol 68:92–98.[ISI][Medline]
Galili D, Berger E, Kaufman E (1991). Pulp narrowing in renal end stage and transplanted patients. J Endod 17:442–443.[ISI][Medline]
Ganibegovic M (2000). Dental radiographic changes in chronic renal disease. Med Arch 54:115–118.
Gavalda C, Bagan JV, Scully C, Silvestre F, Milian M, Jimenez V (1999). Renal haemodialysis patients: oral, salivary, dental and periodontal findings in 105 adult cases. Oral Dis 5:299–302.[ISI][Medline]
Giustiniani S, Robustelli della Cuna FR, Marieni M (1987). Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol 15:247–249.[ISI][Medline]
Greenberg MS, Cohen G (1977). Oral infection in immunosuppressed renal transplant patients. Oral Surg Oral Med Oral Pathol 43:879–885.[ISI][Medline]
Greenspan JS, Greenspan D (1989). Oral hairy leukoplakia: diagnosis and management. Oral Surg Oral Med Oral Pathol 67:396–403.[ISI][Medline]
Grinyo JM, Cruzado JM (2004). Cyclosporine nephrotoxicity. Transplant Proc 36(2 Suppl):240S–242S.[ISI][Medline]
Hall EE (1997). Prevention and treatment considerations in patients with drug-induced gingival enlargement. Curr Opin Periodontol 4:59–63.[ISI][Medline]
Hall EH, Sherman RG, Emmons WW 3rd, Naylor GD (1994). Antibacterial prophylaxis. Dent Clin North Am 38:707–718.[Medline]
Hancock RH, Swan RH (1992). Nifedipine-induced gingival overgrowth. J Clin Periodontol 19:12–14.[ISI][Medline]
Hassell TM, Hefti AF (1991). Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med 2:103–137.
Hay DR, Chambers ST, Ellis-Pegler RB, Jones MR, Leslie PN, Neutze JM (1992). Prevention of infective endocarditis associated with dental treatment and other medical interventions. New Zealand Dent J 88:99–101.
Hernandez G, Arriba L, Jimenez C, Somacarrera ML, Lopez AF, Lucas M, et al. (1998). Effect on gingival overgrowth of replacing ciclosporin-A by FK-506 (abstract). J Dent Res 77(Spec Iss):1253.
Hernandez G, Arriba L, Lucas M, de Andres A (2000). Reduction of severe gingival overgrowth in a kidney transplant patient by replacing ciclosporin A with tacrolimus. J Periodontol 71:1630–1636.[ISI][Medline]
Hogan DJ, Murphy F, Burgess WR, Epstein JD, Lane PR (1985). Lichenoid stomatitis associated with lithium carbonate. J Am Acad Dermatol 13:243–246.[ISI][Medline]
Jaffe EC, Roberts J, Chantler C, Carter JE (1986). Dental findings in chronic renal failure. Br Dent J 160:18–20.[ISI][Medline]
Jaffe EC, Roberts J, Chantler C, Carter JE (1990). Dental maturity in children with chronic renal failure assessed from dental panoramic tomographs. J Int Assoc Dent Child 20:54–58.[Medline]
James JA, Boomer S, Maxwell AP, Hull PS, Short CD, Campbell BA, et al. (2000). Reduction in gingival overgrowth associated with conversion from ciclosporin A to tacrolimus. J Clin Periodontol 27:144–148.[ISI][Medline]
Jameson MD, Wiegmann TB (1990). Principles, uses and complications of haemodialysis. Med Clin North Am 74:945–960.[ISI][Medline]
Kao CH, Hsieh JF, Tsai SC, Ho YJ, Chang HR (2000). Decreased salivary function in patients with end-stage renal disease requiring haemodialysis. Am J Kidney Dis 36:1110–1114.[ISI][Medline]
Kelly WH, Mirahmadi MK, Simon JH, Gorman JT (1980). Radiographic changes of the jawbones in end stage renal disease. Oral Surg Oral Med Oral Pathol 50:372–380.[ISI][Medline]
Kennedy DS, Linden GJ (2000). Resolution of gingival overgrowth following change from ciclosporin to tacrolimus therapy in a renal transplant patient. J Ir Dent Assoc 46:3–4.[Medline]
Kho H, Lee S, Chung SC, Kim YK (1999). Oral manifestations and salivary flow rate, pH, and buffer capacity in patients with end-stage renal disease undergoing haemodialysis. Oral Surg Oral Med Oral Pathol 88:316–319.
Khocht A, Schneider LC (1997). Periodontal management of gingival overgrowth in the heart transplant patient: a case report. J Periodontol 68:1140–1146.[ISI][Medline]
King GN, Thornhill MH (1996). Dental attendance patterns in renal transplant recipients. Oral Dis 2:145–147.[Medline]
King GN, Fullinfaw R, Higgings TJ, Walker RG, Francis DM, Wiesenfeld D (1993). Gingival hyperplasia in renal allograft recipients receiving ciclosporin A and calcium antagonists. J Clin Periodontol 20:286–293.[ISI][Medline]
King GN, Healy CM, Glover MT, Kwan JT, Williams DM, Leigh IM, et al. (1994). Prevalence and risk factors associated with leukoplakia, hairy leukoplakia, erythematous candidosis, and gingival hyperplasia in renal transplant recipients. Oral Surg Oral Med Oral Pathol 78:718–726.[ISI][Medline]
Kirkpatrick TJ, Morton JB (1971). Factors influencing the dental management of renal transplant and dialysis patients. Br J Oral Surg 9:57–64.[Medline]
Klassen JT, Krasko BM (2002). The dental health status of dialysis patients. J Can Dent Assoc 68:34–38.
Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R (2000). Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70:1174–1180.[ISI][Medline]
Koch MJ, Buhrer R, Pioch T, Scharer K (1999). Enamel hypoplasia of primary teeth in chronic renal failure. Pediatr Nephrol 13:68–72.[ISI][Medline]
Koppang HS, Stene T, Solheim T, Larheim TA, Winsnes A, Monn E, et al. (1984). Dental features in congenital persistent renal tubular acidosis of proximal type. Scand J Dent Res 92:489–495.[ISI][Medline]
Korsager B, Spencer ES, Mordhorst CH, Andersen HK (1975). Herpes virus hominis infections in renal transplant recipients. Scand J Infect Dis 7:11–19.[ISI][Medline]
Larato DC (1975). Uremic stomatitis: report of a case. J Periodontol 46:731–733.[ISI][Medline]
Lederman D, Lumernan H, Reuben S, Freedman PD (1984). Gingival hyperplasia associated with nifedipine therapy. Oral Surg Oral Med Oral Pathol 57:620–622.[ISI][Medline]
Lee YW, Gisser SD (1978). Squamous cell carcinoma of the tongue in a nine-year renal transplant survivor. Cancer 41:1–6.[ISI][Medline]
Leonard A, Raij L, Shapiro FL (1973). Bacterial endocarditis in regularly dialyzed patients. Kidney Int 4:407–422.[ISI][Medline]
Levy HM (1988). Dental considerations for the patient receiving dialysis for renal failure. Spec Care Dentist 8:34–36.[Medline]
Ljungman P (2001). Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61:187–196.[ISI][Medline]
Locsey L, Alberth M, Mauks G (1986). Dental management of chronic haemodialysis patients. Int Urol Nephrol 18:211–213.[Medline]
Lohr JW, Schwab SJ (1991). Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 2:961–975.[Abstract]
London GM, Drueke TB (1997). Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 57:1678–1695.
Lumiaho A, Ikaheimo R, Miettinen R, Niemitukia L, Laitinen T, Rantala A, et al. (2001). Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 38:1208–1216.[ISI][Medline]
Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, et al. (1983). Deamino-8-D-arginine vasopressin shortens bleeding time in uremia. N Engl J Med 308:3–12.
Margiotta V, Pizzo I, Pizzo G, Barbaro A (1996). Ciclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, and HLA-antigens. J Oral Pathol Med 25:128–134.[ISI][Medline]
Markitziu A, Katz J, Pisanty S (1986). Lichenoid lesions of oral mucosa associated with ketoconazole. Mykosen 29:317–322.[ISI][Medline]
Massry SG, Ritz E (1978). The pathogenesis of secondary hyperparathyroidism of renal failure: is there a controversy? Arch Intern Med 138(Spec No):853–856.
McCreary CE, Flint SR, McCartan BE, Shields JA, Mabruk M, Toner ME (1997). Uremic stomatitis mimicking oral hairy leucoplakia. Oral Surg Oral Med Oral Pathol 83:350–353.
McDonald SP, Russ GR (editors) (2002). ANZDATA Registry Report, Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia.
McGavin JK, Goa KL (2001). Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61:1153–1183.[ISI][Medline]
McKaig SJ, Kelly D, Shaw L (2002). Investigation of the effect of FK506 (tacrolimus) and cyclosporin on gingival overgrowth following paediatric liver transplantation. Int J Paed Dent 12:398–403.
Michiwaki Y, Michi K, Yamaguchi A (1996). Marked enlargement of jaws in secondary hyperparathyroidism—a case report. Int J Oral Maxillofac Surg 25:54–56.[ISI][Medline]
Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B (1998). The side-effects of ciclosporin A and tacrolimus. Clin Nephrol 49:356–363.[ISI][Medline]
Molpus WM, Pritchard RS, Walker CW, Fitzrandolph FL (1991). The radiographic spectrum of renal osteodystrophy. Am Fam Phys 43:151–158.[ISI][Medline]
Morales JM, Rodriguez-Paternina A, Araque A, Andres A, Hernandez E, Ruilope LM, et al. (1994). Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on ciclosporin therapy: a 5-year prospective randomised study. Transplant Proc 26:2598–2599.[ISI][Medline]
Morisaki I, Kato K, Loyola-Rodriguez JP, Nagata T, Ishida H (1993). Nifedipine-induced gingival overgrowth in the presence of gingival inflammation in rats. J Periodontal Res 28:396–403.[ISI][Medline]
Nadimi H, Bergamini J, Lilien B (1993). Uremic mixed bone disease. A case report. Int J Maxillofac Surg 22:268–270.
Naraqi S, Jackson CG, Jonasson O, Yamashiroya HM (1977). Prospective study of prevalence, incidence and source of herpes virus infections in patients with renal allografts. J Infect Dis 136:531–540.[ISI][Medline]
Nash MM, Zaltzman JS (1998). Efficacy of azithromycin in the treatment of ciclosporin-induced gingival hyperplasia in renal transplant recipients. Transplantation 65:1611–1615.[ISI][Medline]
Nasstrom K (1996). Dentin formation after corticosteroid treatment. A clinical study and an experimental study on rats. Swed Dent J 115:1–45.
Nasstrom K, Forsberg B, Petersson A, Westesson PL (1985). Narrowing of the dental pulp chamber in patients with renal diseases. Oral Surg Oral Med Oral Pathol 59:242–246.[ISI]
